CVS Health company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
An analyst note circulated by Yahoo Finance points to improving earnings indicators for CVS Health alongside peers Cardinal Health, Humana and ACADIA Pharmaceuticals, even as profitability remains under pressure in parts of the healthcare supply chain and managed care.
THE APEX TIMES
THE APEX TIMES
CVS Health says its Health100, a CVS Health subsidiary, has received an industry accreditation tied to consumer-facing data privacy and security expectations.
THE APEX TIMES
A recent analysis frames the debate around CVS Health shares as a question of valuation relative to expected earnings two years from now, not the current headline price.
THE APEX TIMES
The retailer said it has launched its first new neighborhood-focused CVS Pharmacy in Houston, a format designed to broaden access to everyday pharmacy care. CVS also indicated it intends to bring a similar rollout to additional locations.
THE APEX TIMES
Joyner argued that insurers need stronger evidence that current GLP-1 list prices will produce enough “downstream” healthcare savings to justify covering broader use for weight loss.
THE APEX TIMES
A recent look at CVS Health’s stock performance points to a potential mismatch between strong share momentum and what investors appear to be pricing in, with attention focused on the company’s ongoing exposure to antitrust and pricing scrutiny tied to insulin.
THE APEX TIMES
A new market analysis argues that CVS Health’s valuation can look steep if you focus on near-term snapshots, but that the price investors pay may be implicitly tied to expectations for future earnings and cash generation.
THE APEX TIMES
In a Yahoo Finance interview, the leader of CVS Health’s Aetna business discussed how GLP-1 weight-loss medications are reshaping insurer decision-making, from coverage design to medical management.
THE APEX TIMES
A Yahoo Finance market note pointed to an optimistic average brokerage recommendation for CVS Health, even as it raised questions about whether the stock’s recent appeal reflects underlying performance.
